IL-10 and TNF-&amp;#945; polymorphisms in subjects with irritable bowel syndrome in Mexico

Schmulson, Max; Pulido‐London, Daniela; Rodríguez, O. Esparcia; Morales-Rochlin, Norma; Martínez-García, Rosalinda; Gutiérrez‐Ruiz, María Concepción; López-Alvarenga, Juan Carlos; Gutiérrez-Reyes, Gabriela

doi:10.4321/s1130-01082013000700004

Cited by 26 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for the other studies that addressed IBS, their findings are inconsistent since some of the studies that assessed IL-10 genotypes in IBS patients versus controls showed highproducer genotype for IL-10 had a lower frequency statistically significant in IBS than in controls (P = 0.003) [79], and other studies did not find statistically significant difference of IL-10 polymorphism in IBS patients [78]. Schmulson et al [78] assessed two polymorphisms: IL-10 (-1082G/A) and α tumor necrosis factor (-308G/A) in IBS patients and compared them with controls.…”

Section: Genes and Inflammation In Ibsmentioning

confidence: 50%

“…Regarding genes and polymorphism, there are several studies that have assessed gene polymorphism, of which IL-10 and α tumor necrosis factor are some of the ones that are being intensively investigated [77][78][79].…”

Section: Genes and Inflammation In Ibsmentioning

confidence: 99%

“…Schmulson et al [78] assessed two polymorphisms: IL-10 (-1082G/A) and α tumor necrosis factor (-308G/A) in IBS patients and compared them with controls. There were no statistically significant differences between IBS and controls regarding either of the two polymorphisms.…”

Section: Genes and Inflammation In Ibsmentioning

confidence: 99%

See 2 more Smart Citations

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

Section: Genes and Inflammation In Ibsmentioning

confidence: 50%

Section: Genes and Inflammation In Ibsmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

show abstract

“…IBS patients were previously found to have a lower frequency of the high producer IL-10 genotype compared with controls in Turkish patients (Gonsalkorale et al, 2003), and other studies have revealed that the presence of low serum levels of IL-10 is an independent predictive factor of IBS (Schmulson et al, 2013). In addition, women with IBS-D presented with lower IL-10 levels compared to those with IBS-C and IBS-M (Schmulson et al, 2012).…”

Section: Discussionmentioning

confidence: 93%

Correlation between DQB1 genetic polymorphism and genetic susceptibility in patients diagnosed with irritable bowel syndrome with diarrhea

Yu¹,

Huang²,

Zhou³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We examined patients of Han nationality diagnosed with irritable bowel syndrome with diarrhea (IBS-D) in Guangdong, China, to analyze the correlation between DQB1 allele polymorphisms and the genetic susceptibility to IBS-D. A total of 120 IBS-D patients of Han nationality in Guangdong, China, and 60 healthy control volunteers were included. DQB1 allele polymorphisms were investigated by polymerase chain reaction. Subjects' serum interleukin (IL)-10 level, colonic permeability, and tight junction marker zonula occludens 1 (ZO1) mRNA level were also investigated. Our data showed that the DQB1*02 allele frequency was significantly higher in IBS-D patients, while the DQB1*0603 frequency was lower than in healthy volunteers. The DQB1*03, DQB1*04, DQB1*05, DQB1*0601, DQB1*0602, and DQB1*0604 alleles did not show significant differences between IBS-D patients and healthy controls. Furthermore, patients with DQB1*03-positive and DQB1*0603-negative alleles showed more severe colonic permeability and lower serum IL-10 level and ZO1 level compared to healthy controls or even IBS-D patients with other genotypes. The present study indicated the DQB1*02 or DQB1*0603 alleles are related to IBS-D occurrence in Guangdong, China, and the mechanism of the disease may be related to reduced serum IL-10 levels.

show abstract

“…In the present issue of Revista Española de Enfermedades Digestivas Schmulson et al (8) discuss the first association study on the polymorphisms of immune mediators -interleukine (IL) 10 and tumor necrosis factor a (TNF-a)-to be performed in Mexico. Prior studies suggested cytokine signaling disbalance as an etiologic factor for the development of IBS (9,10).…”

Section: A M González-castro Y M Vicariomentioning

confidence: 99%